Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials
Author:
Affiliation:
1. Komen/University of Texas Southwestern Breast Cancer Research Program, University of Texas Southwestern Medical Center, Dallas, Texas,USA
Abstract
Funder
Roche Laboratories
Physicians' Education Resource, Dallas, Texas, USA
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-4-375
Reference104 articles.
1. Extending survival with chemotherapy in metastatic breast cancer;O'Shaughnessy;The Oncologist,2005
2. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort;Chia;Proc Am Soc Clin Oncol,2003
3. Is breast cancer survival improving?;Giordano;Cancer,2004
4. Does survival increase in metastatic breast cancer with recently available anticancer drugs?;Abrial;Oncol Res,2006
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study;Clinical Breast Cancer;2020-06
2. Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells;Frontiers in Immunology;2018-04-19
3. Safety and Efficacy of Low-Dose Metronomic Capecitabine in the Treatment of Elderly Patients with Breast Cancer: Report of Two Cases and Literature Review;International Journal of Gerontology;2016-03
4. HER2 Inhibition and Clinical Achievements;Targeted Therapies in Oncology, Second Edition;2013-10-07
5. Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes;International Journal of Breast Cancer;2013
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3